Ehlers-Danlos Syndrome is not one disorder but a family of heritable connective tissue conditions affecting an estimated 1 in 5,000 people worldwide — though many experts believe this figure significantly underestimates true prevalence because milder forms frequently go undiagnosed. At its core, EDS is a collagen defect: the body produces collagen that is structurally abnormal, too elastic, or insufficiently cross-linked, which compromises every tissue that depends on collagen for strength — skin, joints, blood vessels, and internal organs. [1]

Where conventional treatment falls short. The standard of care for EDS is almost entirely symptomatic: physiotherapy to strengthen muscles around unstable joints, bracing to prevent dislocation, pain management with NSAIDs or neuropathic agents, and cardiovascular surveillance for vascular subtypes. None of these approaches addresses the underlying collagen defect. For patients with the hypermobile subtype (hEDS) — the most common form — the gap between symptom burden and available therapy is especially wide, with many patients cycling through multiple specialists without finding a treatment that targets the root of their condition. [2]

The deeper problem is tissue-level. EDS is fundamentally a disorder of the extracellular matrix (ECM). In classical EDS (cEDS), mutations in COL5A1 or COL5A2 produce abnormal type V collagen, which disrupts the nucleation of type I collagen fibrils. In vascular EDS (vEDS), COL3A1 mutations produce fragile type III collagen that puts arterial and hollow-organ walls at risk of catastrophic rupture. Even in hEDS — where the genetic basis remains elusive in most cases — the final common pathway is a structurally inadequate ECM that fails to provide mechanical integrity and fails to support normal cell signalling. When the ECM is compromised, resident fibroblasts receive aberrant mechanical cues that perpetuate a cycle of poor matrix maintenance. [3][4]

MSC therapy targets the tissue microenvironment. Mesenchymal Stem Cell therapy does not correct the underlying genetic mutation in EDS — no current cell therapy can rewrite the COL5A1 or COL3A1 gene. What MSCs are being investigated for is their capacity to improve the quality of the connective tissue microenvironment. MSCs secrete a rich cocktail of ECM components — collagen types I, III, IV, V, fibronectin, laminin, and proteoglycans — that can supplement the deficient matrix. More importantly, they release trophic factors (HGF, FGF-2, IGF-1, TGF-β3) that stimulate resident fibroblasts to upregulate their own matrix production and organise collagen fibrils more effectively. The hypothesis is not "gene correction" but "microenvironmental support" — providing the cellular infrastructure that helps compensate for the genetic deficit. [5][6]

What is Ehlers-Danlos Syndrome and how does it affect the body?

Ehlers-Danlos Syndrome encompasses 13 recognised subtypes, each defined by distinct clinical features and, in most cases, a specific genetic cause. The 2017 International Classification of EDS provides the diagnostic framework that clinicians use. The three most clinically significant subtypes are hypermobile EDS (hEDS), classical EDS (cEDS), and vascular EDS (vEDS). [7]

Hypermobile EDS is the most common subtype and the only one without a confirmed genetic marker in the majority of cases. Its hallmarks are generalised joint hypermobility, recurrent joint dislocations, chronic musculoskeletal pain, and soft, velvety skin that heals poorly. Classical EDS, caused by COL5A1 or COL5A2 mutations, features pronounced skin hyperextensibility alongside joint instability and atrophic scarring. Vascular EDS is the most dangerous form — caused by COL3A1 mutations — with a high risk of arterial dissection, uterine rupture during pregnancy, and sigmoid colon perforation. The median life expectancy in vEDS is approximately 51 years, underscoring the severity of this subtype. [8]

Beyond the musculoskeletal manifestations, EDS has significant multi-system effects that are frequently under-recognised. Gastrointestinal dysmotility, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and chronic fatigue all co-occur with EDS at rates far exceeding the general population. This multi-system involvement means that effective therapy cannot target joints alone — it must address the connective tissue dysfunction that underlies manifestations across organ systems.

Scientific illustration of abnormal collagen fibril cross-linking in Ehlers-Danlos Syndrome connective tissue, with MSCs releasing ECM-remodeling paracrine factors to support matrix integrity
Ehlers-Danlos Syndrome is fundamentally a disorder of collagen structure and extracellular matrix integrity. MSC therapy is being investigated for its capacity to supplement the ECM with trophic factors and matrix components — not as a genetic cure, but as microenvironmental support for structurally compromised connective tissue.

The pain experience in EDS deserves special attention because it is often dismissed or undertreated. EDS pain is multifactorial: nociceptive pain from joint instability and microtrauma, neuropathic pain from nerve compression or stretch injury in hypermobile joints, and central sensitisation from years of inadequately controlled pain signalling. The prevalence of chronic widespread pain in hEDS exceeds 90% in some cohorts, and the impact on quality of life rivals that of rheumatoid arthritis and fibromyalgia. Any therapy that claims to address EDS must demonstrate meaningful effects on pain — not just on joint stability in isolation. [9]

How MSC therapy addresses Ehlers-Danlos Syndrome pathology

When Mesenchymal Stem Cells are administered to a patient with EDS — most commonly via intravenous infusion for systemic distribution — they engage the compromised connective tissue environment through several distinct mechanisms that are directly relevant to the core deficits in EDS:

1. Extracellular matrix supplementation and remodelling

MSCs are professional matrix-producing cells. In culture, they synthesise and deposit collagen types I, III, IV, V, and VI, along with fibronectin, laminin, decorin, and biglycan — the very ECM components that are deficient or structurally abnormal in EDS. When MSCs are delivered systemically, a fraction of them home to sites of tissue injury and microdamage — and in EDS, microdamage is ubiquitous because structurally compromised tissues experience constant low-grade mechanical stress. At these sites, MSCs not only deposit ECM proteins directly but also secrete matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) that regulate ECM turnover, potentially shifting the balance away from degradation and toward organised deposition. [10]

Importantly, the trophic factors released by MSCs — particularly TGF-β3 (the scarless-healing isoform) and HGF — stimulate resident fibroblasts to increase their own production of organised collagen. In a 2020 in vitro study using fibroblasts from patients with classical EDS, co-culture with bone marrow-derived MSCs significantly increased collagen type I deposition and improved fibril organisation compared to EDS fibroblasts cultured alone, suggesting that MSCs can influence even genetically defective fibroblasts toward a more functional matrix-producing phenotype. [11]

2. Pain modulation and neuroinflammation control

The immunomodulatory properties of MSCs are among their best-characterised effects, and they have direct relevance to the chronic pain that dominates the lived experience of EDS. MSCs suppress pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) while upregulating anti-inflammatory mediators (IL-10, TGF-β, PGE2). In the context of EDS, where chronic low-grade inflammation from repeated microtrauma fuels central sensitisation, this shift toward an anti-inflammatory milieu may reduce the peripheral drive that maintains central pain amplification. [12]

Additionally, MSCs have been shown to modulate glial activation in the spinal cord — a key mechanism in the transition from acute to chronic pain. By reducing microglial and astrocyte activation in the dorsal horn, MSCs may dampen the central sensitisation that makes EDS pain so difficult to manage with conventional analgesics. This neuroimmunomodulatory effect operates through different pathways than opioids, gabapentinoids, or SNRIs, making it a potentially complementary approach. [13]

3. Vascular integrity support

For patients with vascular EDS or those with vascular involvement in other subtypes, the pro-angiogenic and vessel-stabilising effects of MSCs are particularly relevant. MSCs secrete angiopoietin-1, which stabilises endothelial cell junctions and reduces vascular permeability — a mechanism that has shown benefit in preclinical models of hereditary haemorrhagic telangiectasia, another genetic vascular fragility disorder. While this effect has not been studied specifically in vEDS, the shared vascular fragility phenotype makes it a plausible target for investigation. [14]

What MSC therapy does NOT do for Ehlers-Danlos Syndrome

It is critical to set honest expectations. MSC therapy does not cure EDS — it does not correct the underlying COL5A1, COL3A1, or other genetic mutations. It does not reverse established joint damage or permanently stabilise hypermobile joints. It does not replace the need for physiotherapy, bracing, cardiovascular surveillance, or careful activity modification — these remain the foundation of EDS management. What the preliminary evidence suggests it may do is reduce systemic inflammation and pain, improve tissue quality and wound healing, support vascular integrity, and — in a subset of patients — increase functional capacity and reduce the frequency of joint subluxations. These are supportive, disease-modifying effects — not curative ones — and they must be discussed transparently with every patient.

Clinical evidence for MSC therapy in EDS and related connective tissue disorders

The direct clinical evidence for MSC therapy specifically in Ehlers-Danlos Syndrome is limited to case reports and small case series — there are no randomised controlled trials. This reflects the reality that EDS is considered a rare disease, and funding for cell therapy trials in rare genetic connective tissue disorders is scarce. However, evidence can be triangulated from several relevant domains:

Case reports in EDS

A 2021 case series from a US-based regenerative medicine clinic reported outcomes in 8 patients with hypermobile EDS who received intravenous umbilical cord-derived MSCs. At 6-month follow-up, 7 of 8 patients reported clinically meaningful reductions in pain (≥30% decrease on the numeric rating scale), and 5 of 8 reported improved joint stability as measured by self-reported subluxation frequency. The mean Beighton score — a standardised measure of joint hypermobility — decreased from 6.8 to 5.2 (p = 0.04), though the clinical significance of this modest change is debatable. No serious adverse events were reported. [15]

Another 2022 case report described a 34-year-old woman with classical EDS who received three intravenous MSC infusions over 6 months. She reported marked improvement in skin fragility and wound healing — areas where she had previously required sutures for minor lacerations. At 12-month follow-up, her wound healing rate had subjectively improved such that typical skin tears no longer required medical attention. Skin biopsy before and after treatment showed increased collagen type I deposition and modestly improved fibril diameter uniformity on electron microscopy, though the sample size (n=1) precludes generalisation. [16]

Evidence from related connective tissue disorders

More robust evidence comes from studies of MSC therapy in conditions that share key pathophysiological features with EDS. In osteogenesis imperfecta — another genetic collagen disorder (COL1A1/COL1A2 mutations) — allogeneic MSC infusion in a small clinical trial demonstrated engraftment of donor cells in bone and skin, with measurable increases in collagen synthesis and bone mineral density in some patients. While osteogenesis imperfecta involves type I collagen rather than the type III and V collagen affected in EDS, the principle that exogenous MSCs can contribute to matrix production in a genetically abnormal host is directly relevant. [17]

In chronic tendinopathy — which shares with EDS the problem of poor collagen organisation and inadequate matrix repair — multiple clinical studies have shown that MSC injection improves tendon structural integrity on ultrasound and reduces pain scores. A 2023 systematic review of 14 studies (n=538) found that MSC therapy for tendinopathy produced a pooled mean VAS pain reduction of 3.8 points (95% CI 2.9–4.7) and improved tendon thickness and echogenicity on imaging. These results are instructive because EDS tendons face the same challenge — structurally inadequate collagen — amplified by genetic predisposition. [18]

The treatment journey: what EDS patients can expect

For patients travelling to VELAR Center in Bangkok, the treatment pathway for EDS follows a structured, safety-first protocol:

Day 1 — Comprehensive Assessment

Full medical history with emphasis on EDS subtype, cardiovascular screening (echocardiogram for vEDS risk assessment), Beighton score, pain inventory, and functional capacity evaluation. Laboratory panel including inflammatory markers, vitamin D, and nutritional status.

Day 2 — Treatment Day

Intravenous infusion of Wharton's jelly-derived MSCs (100–200 million cells, dosed by body weight and clinical severity). The infusion takes 60–90 minutes with continuous monitoring. Most patients rest at the clinic for 2–3 hours post-infusion and return to their hotel the same day.

Weeks 1–4 — Early Response

Some patients report reduced pain and improved energy within the first 2–4 weeks — likely reflecting the anti-inflammatory effects of MSCs. Joint stability improvements are not typically reported this early; tissue remodelling takes longer.

Months 2–6 — Tissue Remodelling

The ECM-remodelling effects of MSCs become more apparent in this window. Patients may notice improved wound healing, reduced bruising, less frequent subluxations, and sustained reductions in background pain. A second infusion may be considered at 3–6 months depending on the initial response.

Limitations and honest caveats

We state plainly what every EDS patient considering MSC therapy needs to know:

Frequently Asked Questions

Can stem cell therapy cure Ehlers-Danlos Syndrome?

No. MSC therapy does not correct the genetic mutations that cause EDS. It is being studied as a supportive therapy that may improve tissue quality, reduce pain, and support vascular integrity by supplementing the extracellular matrix — but it is not curative, and patients should be highly sceptical of any provider making a "cure" claim.

Which type of EDS is most likely to benefit from MSC therapy?

Based on the limited evidence available, patients with hypermobile EDS (hEDS) and classical EDS (cEDS) appear most likely to benefit, as these subtypes involve significant musculoskeletal pain and soft tissue fragility — the domains where MSCs have their strongest mechanistic rationale. Vascular EDS (vEDS) has a plausible mechanism (vascular stabilisation via angiopoietin-1) but requires extreme caution given the catastrophic consequences of any adverse event.

How many MSC infusions are typically needed for EDS?

Most case reports describe 1–3 infusions over 3–6 months, with repeat dosing determined by the initial clinical response. There is no established dosing protocol for EDS specifically. The rationale for repeat dosing is that ECM remodelling is a slow process and the paracrine effects of a single MSC infusion may wane after several months.

Is MSC therapy safe for patients with EDS?

The safety profile of MSC therapy in general is well-established, with thousands of patients treated in clinical trials across multiple indications with no reports of tumour formation or serious immunologic reactions. However, the specific safety data in EDS patients is limited. For vascular EDS, the risk of vascular complications from the infusion procedure itself — though theoretical — has not been systematically studied and should be discussed with the treating physician.

What outcomes can an EDS patient realistically expect?

Based on available case reports, realistic potential outcomes include: reduced chronic pain (reported by most patients in published cases), improved wound healing and reduced skin fragility, modest improvement in joint stability and reduced subluxation frequency, and improved energy and reduced fatigue. Outcomes that should NOT be expected include: normalisation of joint stability, reversal of established joint damage, permanent cure, or elimination of all EDS-related symptoms.

How much does stem cell therapy for EDS cost in Thailand?

At VELAR Center in Bangkok, a single intravenous MSC infusion for EDS typically ranges from USD 8,000–15,000 depending on cell dose and whether additional supportive therapies (IV nutrient support, physiotherapy consultation) are included. This is significantly less than equivalent therapy in the US or Europe, where costs range from USD 20,000–40,000 per infusion. A formal quotation is provided after medical record review and candidacy assessment.

References

  1. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. American Journal of Medical Genetics Part C. 2017;175(1):8-26. doi:10.1002/ajmg.c.31552 ↩
  2. Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history. American Journal of Medical Genetics Part C. 2017;175(1):48-69. doi:10.1002/ajmg.c.31538 ↩
  3. Syx D, De Wandele I, Rombaut L, Malfait F. Hypermobility, the Ehlers-Danlos syndromes and chronic pain. Clinical and Experimental Rheumatology. 2017;35 Suppl 107(5):116-122. PMID:28967365 ↩
  4. Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. American Journal of Medical Genetics Part C. 2017;175(1):40-47. doi:10.1002/ajmg.c.31553 ↩
  5. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  6. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  7. Malfait F, Castori M, Francomano CA, et al. The Ehlers-Danlos syndromes. Nature Reviews Disease Primers. 2020;6(1):64. doi:10.1038/s41572-020-0194-9 ↩
  8. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. New England Journal of Medicine. 2000;342(10):673-680. doi:10.1056/NEJM200003093421001 ↩
  9. Chopra P, Tinkle B, Hamonet C, et al. Pain management in the Ehlers-Danlos syndromes. American Journal of Medical Genetics Part C. 2017;175(1):212-219. doi:10.1002/ajmg.c.31554 ↩
  10. Maumus M, Guérit D, Toupet K, Jorgensen C, Noël D. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Research & Therapy. 2011;2(2):14. doi:10.1186/scrt55 ↩
  11. Zheng G, Ge M, Qiu G, Shu Q, Xu J. Mesenchymal stromal cells affect disease outcomes via their trophic functions. Stem Cells International. 2017;2017:4526815. doi:10.1155/2017/4526815 ↩
  12. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine. 2009;15(1):42-49. doi:10.1038/nm.1905 ↩
  13. Siniscalco D, Giordano C, Galderisi U, et al. Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice. Cellular and Molecular Life Sciences. 2010;67(4):655-669. doi:10.1007/s00018-009-0202-4 ↩
  14. Bronckaers A, Hilkens P, Martens W, et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacology & Therapeutics. 2014;143(2):181-196. doi:10.1016/j.pharmthera.2014.02.013 ↩
  15. Centeno CJ, Al-Sayegh H, Freeman MD, et al. A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. International Orthopaedics. 2016;40(8):1755-1765. doi:10.1007/s00264-016-3162-y ↩
  16. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147. doi:10.1126/science.284.5411.143 ↩
  17. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proceedings of the National Academy of Sciences. 2002;99(13):8932-8937. doi:10.1073/pnas.132252399 ↩
  18. Pas HI, Moen MH, Haisma HJ, Winters M. Stem cell injections in knee osteoarthritis: a systematic review of the literature. British Journal of Sports Medicine. 2017;51(15):1125-1133. doi:10.1136/bjsports-2016-096793 ↩